Immunome Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
/ 
Frequently asked questions
To buy Immunome Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Immunome Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Immunome Inc. is IMNM:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Immunome Inc. has its primary listing on NASDAQ (Small cap). You can trade Immunome Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Immunome Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Immunome Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Immunome Inc. or others.